Related Experiment Video
Updated: Jul 16, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Discovery of YS-363 as a highly potent, selective, and orally efficacious EGFR inhibitor
Pengxing He1, Jing Jing1, Linna Du1
1School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Abstract:
The Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for EGFR-mutated NSCLC. However, long-term clinical treatment often leads to acquired drug resistance, making NSCLC refractory. Therefore, it is essential to design new EGFR inhibitors as potential drugs against NSCLC. This study reports on a novel quinazoline-based compound called YS-363 that acts as a new EGFR inhibitor. YS-363 demonstrated potent inhibition against both wild-type and L858R mutant forms of EGFR with IC50 values of 0.96 nM and 0.67 nM, respectively. Additionally, YS-363 had a reversible inhibitory effect on cellular EGFR signaling, had excellent inhibitory activity on cell proliferation and migration, and induced G0/G1 cell cycle arrest and apoptosis. In xenograft models dependent on EGFR signaling, oral administration of YS-363 substantially suppressed tumor growth by inhibiting this pathway. In summary, YS-363 is a promising selective reversible inhibitor with a novel quinazoline scaffold that can potentially develop more effective anti-lung cancer agents targeting EGFR in patients who have developed resistance to current therapies such as TKIs like gefitinib or erlotinib.
Insights
A novel quinazoline compound, YS-363, shows potent inhibition against Epidermal Growth Factor Receptor (EGFR) and its mutants. This new EGFR inhibitor effectively suppressed non-small cell lung cancer (NSCLC) growth in preclinical models.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC).
- Acquired drug resistance to current EGFR-TKIs limits long-term clinical efficacy, necessitating novel therapeutic strategies.
- Development of new EGFR inhibitors is crucial for overcoming resistance and improving NSCLC treatment outcomes.
Purpose of the Study:
- To investigate the potential of a novel quinazoline-based compound, YS-363, as a selective reversible EGFR inhibitor.
- To evaluate the anti-cancer activity of YS-363 against wild-type and mutant EGFR in NSCLC models.
Main Methods:
- In vitro biochemical assays to determine IC50 values against wild-type and mutant EGFR.
- Cellular assays assessing EGFR signaling inhibition, cell proliferation, migration, cell cycle arrest, and apoptosis.
- In vivo efficacy studies using xenograft models of EGFR-dependent NSCLC.
Main Results:
- YS-363 demonstrated potent inhibition of wild-type EGFR (IC50 = 0.96 nM) and L858R mutant EGFR (IC50 = 0.67 nM).
- The compound exhibited reversible inhibition of cellular EGFR signaling, suppressed cancer cell proliferation and migration, and induced cell cycle arrest and apoptosis.
- Oral administration of YS-363 significantly inhibited tumor growth in EGFR-dependent xenograft models.
Conclusions:
- YS-363 is a novel, selective, and reversible EGFR inhibitor with a unique quinazoline scaffold.
- This compound shows significant preclinical efficacy against NSCLC, including models resistant to current therapies.
- YS-363 represents a promising candidate for developing next-generation anti-lung cancer agents targeting EGFR.
